Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSVITA vs ARZERRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
Treatment of chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab,Treatment of previously untreated CLL in combination with chlorambucil,Treatment of relapsed CLL in combination with fludarabine and cyclophosphamide
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
Mean terminal elimination half-life after first dose is approximately 14 days (range 7–21 days) and increases with repeated dosing due to target-mediated clearance saturation; at steady state, half-life is ~24 days.
Metabolized into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Ofatumumab is a monoclonal antibody; metabolism is not through typical cytochrome P450 pathways. Clearance involves catabolism to peptides and amino acids.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Arzerra (ofatumumab) is eliminated primarily via the reticuloendothelial system and catabolism; renal excretion is minimal (<1% of dose as intact antibody). Biliary/fecal excretion has not been characterized, but as a monoclonal antibody, it is not significantly excreted in urine or feces.
Target-mediated binding to FGF23; low nonspecific binding to other plasma proteins (typical for m Abs).
As a monoclonal antibody, ofatumumab does not bind to plasma proteins; protein binding is negligible.
3.8 L (approximately 0.05 L/kg for a 70 kg adult); indicates limited extravascular distribution (confined mainly to plasma volume).
Volume of distribution (Vd) is approximately 2.5–4.5 L, approximating plasma volume; does not distribute extensively into tissues (not reported in L/kg, but typical for Ig G1 monoclonal antibodies ~0.1–0.2 L/kg).
Subcutaneous: ~78% relative to intravenous administration (absolute bioavailability not determined due to lack of IV formulation).
Subcutaneous: ~60–70% absolute bioavailability; intravenous: 100%.
No dose adjustment required in renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²) or on dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or hemodialysis; use with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); use with caution.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment recommended for elderly patients (≥65 years). Use based on weight and clinical response.
No specific dose adjustment required for elderly patients. Clinical studies included patients ≥65 years; overall efficacy and safety similar to younger adults, but higher incidence of serious infections and cardiac events observed.
None.
Hepatitis B virus (HBV) reactivation can occur with ofatumumab, leading to fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before initiation. Monitor HBV carriers during and after treatment.
Hypersensitivity reactions including anaphylaxis,Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis,Dental abscesses and infections,Local injection site reactions
Infusion reactions (including anaphylaxis), prolonged cytopenias, progressive multifocal leukoencephalopathy (PML), intestinal obstruction, tumor lysis syndrome, and infections including hepatitis B reactivation.
Concomitant use with phosphate binders or active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol),Severe renal impairment or end-stage renal disease
Known hypersensitivity (anaphylaxis) to ofatumumab or any of its excipients.
Avoid high-phosphorus foods and beverages (e.g., dairy products, nuts, seeds, whole grains, cola, chocolate, organ meats) while on CRYSVITA, as they may increase serum phosphorus levels and risk of hyperphosphatemia. Dietary phosphate restriction is recommended. No specific food-drug interactions known; however, maintain consistent phosphorus intake between doses.
No known food interactions. Take with or without food.
CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of burosumab to pregnant monkeys during organogenesis resulted in no teratogenic effects at doses up to 5.9 times the human dose. However, due to the mechanism of action, potential risks include disturbances in phosphate and vitamin D metabolism which may affect fetal skeletal development. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
ARZERRA (ofatumumab) is a human monoclonal antibody. Ig G molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), there is a potential risk of fetal B-cell lymphocytopenia and impaired immune response. Data from animal studies are insufficient. The drug should be avoided during pregnancy unless the benefit clearly outweighs the risk.
It is not known whether burosumab is excreted in human milk. As a monoclonal antibody, burosumab is likely to be minimally transferred into breast milk and is expected to undergo proteolytic digestion in the gastrointestinal tract. The M/P ratio is unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for CRYSVITA and any potential adverse effects on the breastfed child.
It is unknown whether ofatumumab is excreted in human milk. Human Ig G is present in breast milk, but levels are low. Due to the potential for serious adverse reactions in the breastfed infant (including B-cell depletion), breastfeeding is not recommended during therapy and for at least 6 months after the last dose. No M/P ratio is available.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of burosumab may be altered due to pregnancy-induced physiological changes, including increased plasma volume and altered clearance. Monitor serum phosphorus levels and adjust dosing based on clinical response and tolerability. Consider dose adjustments if significant changes in serum phosphorus or adverse effects occur.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of monoclonal antibodies may be altered due to increased plasma volume and clearance in pregnancy, but no formal studies have been conducted. Use caution and consider therapeutic drug monitoring if available.
CRYSVITA (burosumab) is a recombinant human monoclonal Ig G1 antibody to fibroblast growth factor 23 (FGF23), indicated for X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older. Administer subcutaneously every 2 weeks (pediatric: starting 0.8 mg/kg, max 1.2 mg/kg; adult: 1.0 mg/kg, max 90 mg). Monitor serum phosphorus closely, aiming for age-appropriate normal range. Do not initiate if serum phosphorus is within normal range. Concomitant use with oral phosphate and active vitamin D analogs is not recommended. May cause injection site reactions, headache, and hyperphosphatemia. Discontinue if severe hypersensitivity occurs. Pregnancy and breastfeeding: limited data; use only if clearly needed.
ARZERRA (ofatumumab) is a monoclonal antibody targeting CD20 used in relapsing multiple sclerosis. First dose reactions are common; premedicate with corticosteroids, antihistamines, and antipyretics. Monitor for infections, especially hepatitis B reactivation. Contraindicated in active hepatitis B. Administer as subcutaneous injection; injection site reactions frequent. Live vaccines contraindicated during and after treatment until immune reconstitution.
CRYSVITA is given as an injection under the skin every 2 weeks. Do not miss doses.,Do not take phosphate supplements or active vitamin D (e.g., calcitriol) while on CRYSVITA unless specifically instructed by your doctor.,Report symptoms of high phosphorus levels: muscle cramps, numbness, tingling, or irregular heartbeat.,Common side effects include injection site reactions (redness, pain, swelling), headache, and back pain.,Pregnancy and breastfeeding: inform your doctor if you are pregnant, plan to become pregnant, or are nursing.,Store CRYSVITA in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Allow to reach room temperature before injecting.
Report any signs of infection (fever, chills, cough, painful urination) promptly.,Inform your doctor of any history of hepatitis B infection.,You will receive premedication before the first dose to reduce allergic reactions.,Do not receive live vaccines during treatment or until your doctor confirms immune recovery.,Common side effects include injection site reactions, headache, and fever.,ARZERRA is given as an injection under the skin; rotation of injection sites is recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSVITA vs ARZERRA, answered by our medical review team.
CRYSVITA is a Monoclonal Antibody that works by Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.. ARZERRA is a Antineoplastic, Monoclonal Antibody that works by Ofatumumab is a fully human monoclonal antibody that binds specifically to the CD20 molecule on B lymphocytes, resulting in complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20+ cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSVITA and ARZERRA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSVITA is: 1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.. The standard adult dose of ARZERRA is: ARZERRA (ofatumumab) for chronic lymphocytic leukemia (CLL): Initial dose 300 mg IV, then 1 week later 2000 mg IV weekly for 6 doses, then 2000 mg IV every 4 weeks for up to 4 additional doses. For relapsed CLL: 300 mg IV followed by 1000 mg IV on day 8, then 1000 mg IV on day 15 and day 22 of cycle 1, then 1000 mg IV on day 1 of cycles 2-6 (28-day cycles). Premedicate with acetaminophen, antihistamine, and corticosteroid.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSVITA and ARZERRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSVITA is classified as Category C. CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal stud. ARZERRA is classified as Category C. ARZERRA (ofatumumab) is a human monoclonal antibody. IgG molecules cross the placenta increasingly after the first trimester. Based on its mechanism of action (B-cell depletion), t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.